Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.55 |
| ▸ | NPC1 | O15118 | 9/20 | 0.55 |
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | KDM5A | P29375 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30698327 | 0.88 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2126791 | 0.85 | HPGDS (0.52) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL19322178 | 0.80 | NPC1 (0.56) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2129032 | 0.80 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL15071132 | 0.78 | F2RL1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2127752 | 0.76 | ALDH1A1 (0.75) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL13536268 | 0.76 | HPGD (0.80) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12354846 | 0.76 | HPGD (0.80) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20460439 | 0.76 | HPGD (0.80) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL257545 | 0.76 | HPGD (0.80) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370373-B2 | Antitumor derivatives for differentiation therapy | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194764-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | CLEVELAND CLINIC FOUND (US) | 2018-07-12 | — | — | US | disclosed |
| US-9926316-B2 | Antitumor derivatives for differentiation therapy | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170253589-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | THE CLEVELAND CLINIC FOUNDATION | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194764-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | ALDH1A1 3309/4885NPC1 3167/4885RAB9A 1723/4885 |
| US-20170253589-A1 | ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | ALDH1A1 3309/4885NPC1 3167/4885RAB9A 1723/4885 |
| US-10370373-B2 | Antitumor derivatives for differentiation therapy | MYD88, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | ALDH1A1 3309/4885NPC1 3167/4885RAB9A 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.